Rigerna has achieved another milestone-first patient dosing of leading pipeline drug candidate in a top hospital in China.

RG002 is an innovative siRNA drug developed by Rigerna based on its proprietary platform, such as RIHOST^®, RICMO^®, and LICOD^®.It has obtained IND approvals in both China and Australia, marked as tier-1 C3-targeting siRNA drug candidates worldwide. RG002 has wide potential indications including complement mediated glomerular diseases.

Dr. Li Haitao, CTO of Rigerna, expressed gratitude for the highly efficient and professional work of the teams from Beijing Friendship Hospital, clinical CRO and other partners. "The Phase I clinical trial of RG002 aims to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics. This project is progressing rapidly and steadily according to research plan. The completion of the first patient dosing is an important milestone for the company. We will work together to complete the clinical trials as soon as possible, achieve approval and listing, and provide more efficient, safer, and more economical innovative treatments for patients."